Clinical Trial Update: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) [Phase 3]

View source ↗

Summary

Phase 3 PALOMA-2 trial evaluating palbociclib plus letrozole versus letrozole alone as first-line therapy for postmenopausal women with ER+/HER2- advanced breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2017-04-26